Kaken Pharmaceutical (4521) Q2 2025 earnings summary

Executive summary

• Net sales for the six months ended September 30, 2024, rose 42% year-over-year to ¥51,372 million, driven by strong overseas sales and an upfront payment for an IP transfer.

• Operating profit surged to ¥19,579 million, up 355% year-over-year, reflecting higher sales and stable SG&A expenses.

• Profit attributable to owners increased 351% year-over-year to ¥14,286 million.

• Comprehensive income increased 131.7% year-over-year to ¥13,469 million.

Financial highlights

• Gross profit increased to ¥34,103 million from ¥19,720 million year-over-year.

• Domestic pharmaceuticals and medical devices sales grew 3.7% year-over-year, mainly due to increased Artz sales after a competitor's exit.

• Overseas and bulk substance sales soared 635.9% year-over-year, largely from the NM26 IP transfer payment.

• R&D expenses increased 4.1% year-over-year to ¥5,973 million, reflecting progress in development projects.

• Cash and cash equivalents rose by ¥13,926 million year-over-year to ¥83,987 million.

Outlook and guidance

• FY2024 net sales forecast revised upward to ¥88,500 million (up 22.8% year-over-year), with operating profit expected at ¥20,800 million (up 118.6%).

• Profit attributable to owners for the full year is forecast at ¥14,200 million (up 76.9%).

• Basic earnings per share for the full year is forecast at ¥374.93.

• Upward revision driven by the NM26 IP transfer and commercial option agreement.

• Dividend payout planned at ¥190 per share for FY2025 (including a ¥40 bonus).